Drug Trial Radar · NCT00103662
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients
Last checked: Nov 20, 2026Latest source record: Mar 13, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
302
Actual
Start
Jan 2005
Primary completion
Oct 2006
Study completion Jan 2008
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 14, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 78 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF, generic name of filgrastim) is better than G-CSF alone to mobilize and collect the optimal number of stem cells in multiple myeloma patients for autologous transplantation.
Conditions
- Multiple Myeloma
Interventions
Granulocyte colony-stimulating factor plus plerixaforDrug
Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
Granulocyte colony-stimulating factor plus placeboDrug
Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants Achieving a Target of ≥ 6*10^6 CD34+ Cells/kg in 2 or Fewer Days of Apheresis.Time frame: up to Day 6
Locations
39 sites in 3 countries. Site status is shown where the registry gives one.
City of Hope Samaritan Bone Marrow Transplant Program
Phoenix, Arizona
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
Little Rock, Arkansas
City of Hope National Medical Center
Duarte, California
Cedars-Sinai
Los Angeles, California
University of California
Los Angeles, California
Rocky Mountain Cancer Center
Denver, Colorado
Yale University School of Medicine
New Haven, Connecticut
University of Florida
Gainesville, Florida
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Emory University
Atlanta, Georgia
Loyola University Medical Center
Maywood, Illinois
Indiana Blood and Marrow Transplantation Center
Beech Grove, Indiana
University of Iowa Hosptials and Clinics
Iowa City, Iowa
Fairview-University Medical Center, University of Minnesota
Minneapolis, Minnesota
Mayo Clinic
Rochester, Minnesota
Kansas City Cancer Center
Kansas City, Missouri
Washington University School of Medicine, Division of Bone Marrow Transplantation and Leukemia
St Louis, Missouri
The Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
St. Vincent's Comprehensive Cancer Center
New York, New York
New York Hospital
New York, New York
Memorial Sloan Kettering
New York, New York
University of Rochester Medical Center
Rochester, New York
Duke University Medical Center
Durham, North Carolina
Case Western Reserve University
Cleveland, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio
Ohio State University
Columbus, Ohio
Oregon Health & Science University
Portland, Oregon
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania
The University of Texas MD Anderson Cancer Center
Houston, Texas
Wilford Hall Medical Center
Lackland Air Force Base, Texas
Texas Transplant Institute
San Antonio, Texas
University of Texas Health Science Center
San Antonio, Texas
Utah Blood and Marrow Transplant Program, University of Utah
Salt Lake City, Utah
Virginia Commonwealth University
Richmond, Virginia
Fred Hutchinson Cancer Research Center
Seattle, Washington
Vancouver General Hospital
Vancouver, British Columbia, Canada
Universitätsklinikum Heidelberg,
Heidelberg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.